Purple Biotech Ltd
Purple Biotech Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing oncology immunotherapy candidates. Its work centers on a tri-specific antibody platform designed to activate both T cells and NK cells against solid tumors, with development programs carried out from its Rehovot, Israel base and funded through public-market capital.
Business
Share of revenueCAPTN-3 and its lead candidate IM1240, which are being advanced as oncology immunotherapy assets.
Earlier-stage candidates such as IM1305 that broaden the platform beyond the lead program.
Tri-specific antibody engineering and proprietary capping technology used to design tumor-selective molecules.
Customers
Purple Biotech does not sell commercial medicines; its direct counterparties are research partners, clinical collaborators, and capital providers that support drug development. The eventual end customers for approved products would be oncology physicians, hospitals, and cancer patients, but today the business is primarily oriented toward advancing drug candidates through development milestones. Its collaborations also indicate engagement with external technology partners to accelerate antibody design.
Buy equity exposure to the clinical-stage pipeline and platform value.
Collaborate on design, optimization, and acceleration of antibody candidates.
Hospitals, investigators, and CROs support development of oncology candidates.
Would use approved therapies for solid-tumor treatment if programs succeed.
Strategy
Purple Biotech’s strategy is to advance a differentiated oncology platform built around conditionally activated tri-specific antibodies and to extend that platform into multiple drug candidates. It is also using external collaborations, including AI-enabled design partnerships, to improve discovery speed and molecule quality while broadening the pipeline.
Clinical progress is the main driver of platform validation and future value creation.
A broader pipeline reduces dependence on a single program and increases partnering optionality.
AI-enabled design can shorten discovery cycles and improve candidate quality.
Geography
Purple Biotech is headquartered in Rehovot, Israel and is publicly listed on Nasdaq and the Tel Aviv Stock Exchange. Its development work is centered in Israel, while its capital access and investor base are international through U.S. and Israeli public markets. The company’s clinical and partnership footprint can extend beyond Israel as candidates progress into broader oncology development.
Risks
Purple Biotech faces the typical risks of a clinical-stage biotechnology company: programs may fail in preclinical or clinical development, timelines can be long and uncertain, and future value depends on successful validation of a narrow pipeline. As a public Israeli company with U.S. listing exposure, it also depends on capital markets access and continued Nasdaq compliance, while research partnerships and scientific execution remain critical to its strategy.
- Clinical development failureImpact: CriticalLikelihood: High
The pipeline is preclinical/clinical-stage, so efficacy or safety issues could halt programs.
Exposure - Capital market dependenceImpact: HighLikelihood: High
Biotech development requires ongoing funding before any product revenue exists.
Exposure: General corporate funding and R&D spend
- Scientific development riskImpact: HighLikelihood: High
Tri-specific antibodies and tumor-selective activation are technically complex to design and validate.
Exposure: Platform engineering and translational biology
- Listing and liquidity riskImpact: MediumLikelihood: Medium
Maintaining exchange compliance is important for trading access and financing flexibility.
Exposure: Nasdaq Capital Market listing
Accounting
Judgemental itemsWarrants are marked to market and can create non-cash volatility in reported profit or loss.
Impact: Can materially affect periodic earnings and equity
Employee and director equity awards are expensed over vesting periods, affecting operating costs.
Impact: Influences R&D and G&A expense
Clinical and preclinical spending is typically expensed as incurred, not capitalized like a product asset.
Impact: Makes current-period losses reflect development intensity
Office and facility leases create right-of-use assets and liabilities under IFRS 16.
Impact: Affects leverage and finance expense
Actuarial assumptions influence pension or severance-related liabilities.
Impact: Can move equity and operating costs
Similar listed companies
Publicly listed companies with a comparable business focus.
Compugen Ltd
CGEN · Biological Products, (No Diagnostic Substances)
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
PureTech Health plc
PTCHF · Pharmaceutical Preparations
PureTech Health plc is a biotherapeutics company that builds and develops a portfolio of science-based medicines and related technologies through a hub-and-spoke model.
Active Biotech
ACTI · Health Care
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications.
CollPlant Biotechnologies Ltd
CLGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last updated: 28/09/2026